A gene therapy for a rare genetic disorder has been the subject of recent developments, with the FDA initially rejecting a gene therapy from Regenxbio for the condition. However, the FDA has since approved a drug for the same condition, known as Hunter syndrome, from a different company, Denali. The status of Regenxbio's gene therapy is unclear, with reports indicating both a rejection and potential resubmission.